179 related articles for article (PubMed ID: 29061028)
1. Inhibitory Effects of Panduratin A on Periodontitis-Induced Inflammation and Osteoclastogenesis through Inhibition of MAPK Pathways In Vitro.
Kim H; Kim MB; Kim C; Hwang JK
J Microbiol Biotechnol; 2018 Feb; 28(2):190-198. PubMed ID: 29061028
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory Effects of
Kim H; Kim C; Kim DU; Chung HC; Hwang JK
J Microbiol Biotechnol; 2018 Mar; 28(3):357-366. PubMed ID: 29212295
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory Effects of
Kim S; Kook KE; Kim C; Hwang JK
J Microbiol Biotechnol; 2018 Aug; 28(8):1270-1281. PubMed ID: 29996622
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory Effects of Standardized Boesenbergia pandurata Extract and Its Active Compound Panduratin A on Lipopolysaccharide-Induced Periodontal Inflammation and Alveolar Bone Loss in Rats.
Kim H; Kim C; Kook KE; Yanti ; Choi S; Kang W; Hwang JK
J Med Food; 2018 Oct; 21(10):961-970. PubMed ID: 30088980
[TBL] [Abstract][Full Text] [Related]
5. Palmitoleic Acid Inhibits RANKL-Induced Osteoclastogenesis and Bone Resorption by Suppressing NF-κB and MAPK Signalling Pathways.
van Heerden B; Kasonga A; Kruger MC; Coetzee M
Nutrients; 2017 Apr; 9(5):. PubMed ID: 28452958
[TBL] [Abstract][Full Text] [Related]
6. Myricetin suppresses LPS-induced MMP expression in human gingival fibroblasts and inhibits osteoclastogenesis by downregulating NFATc1 in RANKL-induced RAW 264.7 cells.
Ko SY
Arch Oral Biol; 2012 Dec; 57(12):1623-32. PubMed ID: 22795564
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of panduratin A on c-Jun N-terminal kinase and activator protein-1 signaling involved in Porphyromonas gingivalis supernatant-stimulated matrix metalloproteinase-9 expression in human oral epidermoid cells.
Yanti ; Lee M; Kim D; Hwang JK
Biol Pharm Bull; 2009 Oct; 32(10):1770-5. PubMed ID: 19801842
[TBL] [Abstract][Full Text] [Related]
8. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Li L; Sapkota M; Kim SW; Soh Y
Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730
[TBL] [Abstract][Full Text] [Related]
9. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
10. Aminothiazoles inhibit RANKL- and LPS-mediated osteoclastogenesis and PGE2 production in RAW 264.7 cells.
Kats A; Norgård M; Wondimu Z; Koro C; Concha Quezada H; Andersson G; Yucel-Lindberg T
J Cell Mol Med; 2016 Jun; 20(6):1128-38. PubMed ID: 26987561
[TBL] [Abstract][Full Text] [Related]
11. Hesperetin suppresses RANKL-induced osteoclastogenesis and ameliorates lipopolysaccharide-induced bone loss.
Liu H; Dong Y; Gao Y; Zhao L; Cai C; Qi D; Zhu M; Zhao L; Liu C; Guo F; Xiao J; Huang H
J Cell Physiol; 2019 Jul; 234(7):11009-11022. PubMed ID: 30548260
[TBL] [Abstract][Full Text] [Related]
12. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
13. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
14. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
15. Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells.
Yoon WJ; Kim KN; Heo SJ; Han SC; Kim J; Ko YJ; Kang HK; Yoo ES
Biochem Biophys Res Commun; 2013 May; 434(4):892-7. PubMed ID: 23611776
[TBL] [Abstract][Full Text] [Related]
16. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
17. BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction.
Meng S; Zhang L; Tang Y; Tu Q; Zheng L; Yu L; Murray D; Cheng J; Kim SH; Zhou X; Chen J
J Dent Res; 2014 Jul; 93(7):657-62. PubMed ID: 24799421
[TBL] [Abstract][Full Text] [Related]
18. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
19. Lipoxin A4 suppresses osteoclastogenesis in RAW264.7 cells and prevents ovariectomy-induced bone loss.
Liu C; Guan H; Cai C; Li F; Xiao J
Exp Cell Res; 2017 Mar; 352(2):293-303. PubMed ID: 28209487
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]